Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride This paper reflects the scientific opinion of the authors and not the policies of regulating agencies. A project of the International Pharmaceutical Federation FIP, Groupe BCS, http://www.fip.org/bcs .
dc.contributor.author | Becker, C. | en_US |
dc.contributor.author | Dressman, Jennifer B. | en_US |
dc.contributor.author | Amidon, Gordon L. | en_US |
dc.contributor.author | Junginger, H. E. | en_US |
dc.contributor.author | Kopp, S. | en_US |
dc.contributor.author | Midha, Kamal K. | en_US |
dc.contributor.author | Shah, V. P. | en_US |
dc.contributor.author | Stavchansky, S. | en_US |
dc.contributor.author | Barends, D. M. | en_US |
dc.date.accessioned | 2008-03-06T19:09:25Z | |
dc.date.available | 2009-04-09T15:01:14Z | en_US |
dc.date.issued | 2008-04 | en_US |
dc.identifier.citation | Becker, C.; Dressman, J.B.; Amidon, G.L.; Junginger, H.E.; Kopp, S.; Midha, K.K.; Shah, V.P.; Stavchansky, S.; Barends, D.M. (2008). "Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride This paper reflects the scientific opinion of the authors and not the policies of regulating agencies. A project of the International Pharmaceutical Federation FIP, Groupe BCS, http://www.fip.org/bcs . ." Journal of Pharmaceutical Sciences 97(4): 1350-1360. <http://hdl.handle.net/2027.42/58024> | en_US |
dc.identifier.issn | 0022-3549 | en_US |
dc.identifier.issn | 1520-6017 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/58024 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17879380&dopt=citation | |
dc.description.abstract | Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing ethambutol dihydrochloride as the only active pharmaceutical ingredient (API) are reviewed. Ethambutol dihydrochloride is a Biopharmaceutics Classification System (BCS) Class III drug with permeability properties approaching the border between BCS Class I and III. BE problems of ethambutol formulations containing different excipients and different dosages forms have not been reported and hence the risk of bio in equivalence caused by excipients is low. Ethambutol has a narrow therapeutic index related to ocular toxicity. However, as long as the prescribers' information of the test product stipulates the need for regular monitoring of ocular toxicity, the additional patient risk is deemed acceptable. It is concluded that a biowaiver can be recommended for IR solid oral dosage forms provided that the test product (a) contains only excipients present in ethambutol IR solid oral drug products approved in ICH or associated countries, for instance as presented in this paper, (b) complies with the criteria for “very rapidly dissolving” and (c) has a prescribers' information indicating the need for testing the patient's vision prior to initiating ethambutol therapy and regularly during therapy. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:1350–1360, 2008 | en_US |
dc.format.extent | 158477 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Chemistry | en_US |
dc.subject.other | Food Science, Agricultural, Medicinal and Pharmaceutical Chemistry | en_US |
dc.title | Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride This paper reflects the scientific opinion of the authors and not the policies of regulating agencies. A project of the International Pharmaceutical Federation FIP, Groupe BCS, http://www.fip.org/bcs . | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main, Germany | en_US |
dc.contributor.affiliationother | Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main, Germany | en_US |
dc.contributor.affiliationother | Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand | en_US |
dc.contributor.affiliationother | World Health Organization, Geneva, Switzerland | en_US |
dc.contributor.affiliationother | University of Saskatchewan, Saskatoon, Saskatchewan, Canada | en_US |
dc.contributor.affiliationother | International Pharmaceutical Federation FIP, Den Haag, The Netherlands | en_US |
dc.contributor.affiliationother | Division of Pharmaceutics, College of Pharmacy, University of Texas at Austin, Austin, Texas | en_US |
dc.contributor.affiliationother | RIVM—National Institute for Public Health and the Environment, Bilthoven, The Netherlands ; RIVM—National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Telephone: +31-30-2744209; Fax: +31-30-2744462 | en_US |
dc.identifier.pmid | 17879380 | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/58024/1/21061_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/jps.21061 | en_US |
dc.identifier.source | Journal of Pharmaceutical Sciences | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.